Vir Biotechnology, Inc.
- Open
- 10.91
- Day high
- 11.39
- Day low
- 10.80
- Prev close
- 10.94
- Volume
- 390K
- Mkt cap
- $1.9B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.0
- P/S
- 6.4
- Yield
- —
- Per share
- —
Vir Biotechnology, Inc. (VIR) is a Healthcare company listed on NASDAQ. The stock is up 116% over the past year.
Vir Biotechnology, Inc. (VIR) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
VIR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $0.33 | $0.47 | +41.3% | $239M | +75.8% |
| May 6, 2026 | $-0.01 | $-0.85 | -8400.0% | $-29000 | -100.1% |
| Feb 23, 2026 | $-0.42 | $-0.31 | +26.2% | $64M | +2940.3% |
| Nov 5, 2025 | $-0.70 | $-1.17 | -67.1% | — | — |
| Feb 26, 2025 | $-0.85 | $-0.76 | +10.6% | $12M | +45.5% |
| Oct 31, 2024 | $-0.96 | $-1.56 | -62.5% | $2M | -74.6% |
| Aug 1, 2024 | $-0.93 | $-1.02 | -9.7% | $3M | -59.0% |
| May 2, 2024 | $-0.99 | $-0.48 | +51.5% | $56M | +381.4% |
| Feb 22, 2024 | $-1.14 | $-0.86 | +24.6% | $17M | +25.0% |
| Nov 2, 2023 | $-1.21 | $-1.22 | -0.8% | $4M | -60.0% |
| Aug 3, 2023 | $-1.21 | $-1.45 | -19.8% | $13M | -50.9% |
| May 4, 2023 | $-0.81 | $-1.06 | -30.9% | $47M | -6.8% |
VIR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 10, 2026 | Coughlin Timothydirector | Grant | 8,000 | — |
| Jun 10, 2026 | Coughlin Timothydirector | Grant | 16,000 | $8.51 |
| Jun 2, 2026 | Sabatini Brentofficer: SVP, Chief Accounting Officer | Sell | 379 | $9.45 |
| Jun 2, 2026 | Napolitano Janetdirector | Sell | 3,200 | $9.45 |
| May 28, 2026 | Sigal Charles Elliottdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Sigal Charles Elliottdirector | Grant | 8,000 | — |
| May 28, 2026 | Napolitano Janetdirector | Grant | 8,000 | — |
| May 28, 2026 | BISCHOFBERGER NORBERT Wdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | MORE ROBERT Jdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Napolitano Janetdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Hatfield Jeffrey S.director | Grant | 8,000 | — |
| May 28, 2026 | Farid Ramydirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Hatfield Jeffrey S.director | Grant | 16,000 | $9.10 |
| May 28, 2026 | MORE ROBERT Jdirector | Grant | 8,000 | — |
| May 28, 2026 | BISCHOFBERGER NORBERT Wdirector | Grant | 8,000 | — |
Source: VIR SEC Form 4 filings, latest Jun 10, 2026. For informational purposes only — not investment advice.
See the full VIR insider & 13F page →Vir Biotechnology, Inc. company profile
Overview
Vir Biotechnology, Inc. (NASDAQ:VIR) is a commercial-stage immunology company founded in 2016 and headquartered in San Francisco, California. The company went public in October 2019 and focuses on developing therapeutic products to treat and prevent serious infectious diseases. Vir gained significant attention during the COVID-19 pandemic with its SARS-CoV-2 neutralizing antibody Sotrovimab (marketed as Xevudy), which generated substantial revenue in 2022. However, the company has since pivoted away from COVID-19 treatments and is now primarily focused on developing treatments for hepatitis B and hepatitis delta viruses, while also expanding into oncology through T-cell engager therapies acquired from Sanofi in 2024.
Business
Vir Biotechnology operates in the biotechnology sector, specifically developing immunology-based treatments for infectious diseases and, more recently, oncology applications. The company's approach centers on leveraging the human immune system to combat diseases through monoclonal antibodies, siRNA therapeutics, and advanced T-cell engager platforms. The company's core pipeline consists of three main therapeutic areas: 1. **Hepatitis Delta Virus (HDV) Treatment** - Vir's lead program focuses on treating hepatitis delta, a severe form of viral hepatitis that affects approximately 7 million patients globally with active viremic RNA-positive infections. The company is developing a combination therapy of tobevibart (a monoclonal antibody) and elebsiran (an siRNA therapeutic) that targets both the hepatitis B and delta viruses simultaneously. This represents the company's most advanced program, currently preparing for Phase III trials. 2. **Hepatitis B Virus (HBV) Functional Cure** - The company is developing combination therapies aimed at achieving a "functional cure" for chronic hepatitis B, meaning patients would no longer require ongoing treatment. This involves combinations of VIR-2218 (siRNA), VIR-3434 (capsid assembly modulator), and potentially interferon to eliminate hepatitis B surface antigen from patients. 3. **Oncology T-Cell Engagers** - Through a 2024 licensing agreement with Sanofi, Vir acquired three clinical-stage masked T-cell engager programs: VIR-5818 (targeting HER2-positive cancers), VIR-5500 (targeting PSMA-positive prostate cancers), and VIR-5525 (targeting EGFR-positive cancers). These therapies use a dual-masking technology called PRO-XTEN that activates the treatment specifically in tumor environments while minimizing systemic toxicity. The hepatitis programs likely represent approximately 70-80% of the company's current R&D focus, with the newly acquired oncology platform comprising the remaining 20-30% based on recent resource allocation and strategic priorities outlined in earnings calls.
Revenue model
Vir Biotechnology's business model has evolved significantly since its founding. The company initially generated substantial revenue through collaboration agreements, particularly the $1.58 billion earned in 2022 primarily from its COVID-19 antibody Sotrovimab through partnerships with GSK. However, with the decline of COVID-19 treatment demand, the company has transitioned to a more traditional biotech development model. Currently, Vir operates primarily as a clinical-stage biotechnology company that will eventually monetize its pipeline through several mechanisms: **Product Sales and Licensing**: The company's primary future revenue will come from direct sales of approved therapeutics and licensing agreements with pharmaceutical partners. For hepatitis delta, Vir plans to commercialize independently in major markets, while seeking partners for hepatitis B development and commercialization. **Milestone Payments and Royalties**: The Sanofi transaction demonstrates this model - Vir received $100 million upfront plus $75 million in milestones for licensing three T-cell engager programs, with potential for additional development and commercial milestones. **Collaboration Revenue**: The company maintains various research collaborations with organizations like the Bill & Melinda Gates Foundation and NIH, providing grant funding for specific programs. Several factors significantly impact Vir's financial prospects and margins. **Positive factors** include the large addressable markets for hepatitis treatments (estimated 61,000 RNA-positive HDV patients in the US alone), potential for premium pricing given limited competition in hepatitis delta, and the breakthrough therapy designations that could accelerate regulatory approval. The company's strong cash position of approximately $1 billion provides runway into mid-2027, reducing financing risk during critical development phases. **Negative factors** include the high cash burn rate of approximately $80-90 million per quarter, intense competition in oncology markets where larger pharmaceutical companies dominate, and the inherent clinical development risks where programs could fail in late-stage trials. The company also faces pressure to secure partnerships for some programs, as evidenced by Alnylam's decision not to opt into the hepatitis B profit-sharing arrangement, which could indicate market skepticism about commercial potential.
Competitive moat
Vir Biotechnology's competitive moat is relatively narrow and primarily based on intellectual property and first-mover advantages rather than sustainable structural advantages. The company's strongest moat exists in hepatitis delta treatment, where it appears to be among the first to develop a combination therapy approach targeting both hepatitis B and delta viruses simultaneously. The breakthrough therapy and fast track designations from the FDA provide regulatory advantages and could result in faster market entry. The company's PRO-XTEN dual-masking platform for T-cell engagers represents a potentially differentiated technology that could provide some competitive protection through patents and know-how. This platform's ability to selectively activate therapeutics in tumor environments while minimizing systemic toxicity could offer advantages over competing T-cell engager approaches. However, Vir's moat is fundamentally weak in several respects. In hepatitis treatments, larger pharmaceutical companies with greater resources and established hepatology franchises could develop competing approaches or acquire competing assets. The company lacks the commercial infrastructure and market presence of established players like Gilead Sciences in hepatitis treatments. In oncology, Vir faces intense competition from well-funded biotechnology companies and major pharmaceutical corporations with extensive T-cell engager programs and superior manufacturing capabilities. The company's financial resources, while substantial at $1 billion in cash, are finite and may not be sufficient to fully develop and commercialize multiple programs simultaneously. This creates vulnerability to larger competitors who can sustain longer development timelines and multiple program failures. Additionally, the company's dependence on partnerships for some programs, as evidenced by the need to find a hepatitis B development partner, suggests limited ability to independently advance its full pipeline. The regulatory environment also presents both opportunities and risks - while breakthrough designations provide advantages, regulatory approval is never guaranteed, and competitors could potentially achieve similar regulatory benefits for their own programs.
Risks & safety
Vir Biotechnology presents a moderate margin of safety profile typical of clinical-stage biotechnology companies, with both significant financial cushion and substantial execution risks. **Cash Position and Runway**: - Strong liquidity with approximately $1 billion in cash and short-term investments - Current quarterly cash burn of $80-90 million provides runway into mid-2027 - No significant debt burden (debt-to-equity ratio of 0.09) - Excellent current ratio of 6.79 indicating strong short-term liquidity **Valuation Metrics**: - Trading at 0.85x book value, suggesting potential undervaluation relative to net assets - Graham net-net ratio of 3.91 indicates trading below liquidation value - Negative earnings make traditional P/E ratios less meaningful - Enterprise value reflects the cash-rich balance sheet **Key Risk Factors**: - High cash burn rate creates time pressure for clinical milestones - Single-asset concentration risk in hepatitis delta program - Regulatory approval uncertainty for all pipeline programs - Potential need for additional financing if development timelines extend - Limited revenue diversification following COVID-19 program wind-down
Recent development
Over the past two years, Vir Biotechnology has undergone a significant strategic transformation, moving away from its COVID-19 focus toward a more concentrated pipeline in hepatitis treatments and oncology. The most significant development was the 2024 acquisition of three clinical-stage T-cell engager programs from Sanofi for $175 million, providing Vir with exclusive worldwide rights to HER2, PSMA, and EGFR-targeted therapies using the proprietary PRO-XTEN dual-masking platform. The company implemented a major restructuring in 2024, reducing its workforce by approximately 25% and phasing out several programs including influenza, COVID-19, and T-cell-based viral vector platforms. This strategic refocusing generated approximately $50 million in annual cost savings while concentrating resources on the most promising assets. In hepatitis delta, Vir advanced its combination therapy through the SOLSTICE Phase II trial, achieving breakthrough therapy and fast track designations from the FDA. The program demonstrated impressive efficacy with 80% of patients achieving viral suppression at 60 weeks in the rollover cohort. The company is now preparing to initiate the ECLIPSE Phase III registrational program in the first half of 2025. The hepatitis B program has shown promising signals toward achieving functional cure rates, with the company targeting 30% functional cure with interferon combination and 20% without interferon. However, following Alnylam's decision not to opt into the profit-sharing arrangement, Vir is actively seeking a development and commercialization partner for this program. In oncology, the newly acquired T-cell engager programs have shown early clinical promise, with VIR-5818 demonstrating a 33% confirmed partial response rate in HER2-positive colorectal cancer and VIR-5500 showing 100% PSA decline in prostate cancer patients at therapeutic doses. The company plans to initiate the third program, VIR-5525 targeting EGFR, in the first quarter of 2025.
VIR company profile · for informational purposes only — not investment advice.
Track VIR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free